Stay updated on Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThis updates the ClinicalTrials.gov page’s revision/version indicator from v3.5.2 to v3.5.3, reflecting a platform release rather than a change to the underlying study information.SummaryDifference0.1%

- Check18 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedResults posted with expanded outcome measures (ORR, TTR, Recurrence Free Survival, OS) and biomarker analyses, plus related study documents.SummaryDifference2%

- Check47 days agoChange DetectedMeSH terms now include Hepatocellular carcinoma (HCC) and a link to the Genetic and Rare Diseases Information Center; the page footer shows Revision: v3.5.0, replacing v3.4.3.SummaryDifference0.2%

- Check54 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded Revision: v3.4.2 and removed the previous Revision: v3.4.1 notice, along with removing the funding status operating notice.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.